(2024) , environ 25 % de la perte de poids totale sous analogues du GLP-1 correspondrait de la masse maigre (essentiellement du muscle), et non de la graisse
Lancet Diabetes Endocrinol 6(4):275286 Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL et al (2023) The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
The goal is to activate GLP-1 in the body naturally, which helps balance appetite and insulin release
Commonly used GLP-1 RAs include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity)